Table 1: Baseline and follow-up measures for men with prostate cancer participating in a presurgical weight loss trial (n = 32).

Baseline Mean ± SD Follow-up Mean ± SD Change Mean ± SD
Body weight (kg) 96.4 ± 13.8 93.0 ± 13.3 -3.4 ± 3.9***
Body Mass Index (kg/m2) 31.1 ± 4.4 30.0 ± 4.2 -1.1 ± 1.3***
Percent body fata 36.0 ± 5.5 34.6 ± 5.5 -1.4 ± 1.9***
Caloric Intakeb 1587 ± 525 1298 ± 432 289 ± 667*
Stage 1 VO2 10.1 ± 1.9 9.6 ± 2.0 -0.4 ± 1.7
Stage 2 VO2 13.1 ± 2.1 12.5 ± 2.2 -0.5 ± 2.2
Stage 1 HR 96.1 ± 13.3 90.1 ± 13.3 -6.0 ± 9.9**
Stage 2 HR 106.8 ± 14.2 100.1 ± 13.3 -6.7 ± 10.6**
Stage 1% of max HR 0.601 ± 0.086 0.563 ± 0.087 -0.038 ± 0.062**
Stage 2% of max HR 0.667 ± 0.088 0.626 ± 0.086 -0.041 ± 0.066**
Predicted VO2max 25.0 ± 2.0 25.8 ± 2.1 0.8 ± 1.5**
Predicted Lean mass VO2maxa 42.0 ± 1.4 41.7 ± 1.4 -0.3 ± 1.1

an = 31 due to no DEXA data; bAverage of two-24 hour dietary recalls, n = 28; Stage 1: 3.22 km/hr, no incline; Stage 2: 3.22 km/hr, 4% incline; *p < 0.01; **p < 0.05; ***p < 0.001, significant at p < 0.004.